UCB, Dr. Reddy's, Others Settle Keppra Litigation

Law360, New York (October 5, 2007, 12:00 AM EDT) -- Belgian pharmaceutical company UCB has struck settlement deals with Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories Inc. and Cobalt Pharmaceuticals Inc., resolving pending patent litigation in Georgia over UCB's epilepsy treatment Keppra.

The settlement agreements pertain to cases Brussels-based UCB Societe Anonyme and its U.S. subsidiary UCB Pharma Inc. filed in the northern district of Georgia.

The pact with Mylan will allow Mylan to market 250 mg, 500 mg and 750 mg generic levetiracetam—the active ingredient in Keppra—tablets in the U.S. beginning on Nov. 1, 2008 provided...
To view the full article, register now.